title: Advances in multiple myeloma and spine disease.
abstract: Progressive bone destruction is the hallmark of multiple myeloma (MM) and is responsible for principal morbidity in the disease. The spine is the most afflicted skeletal organ, and vertebral fractures have significantly contributed to its poor prognosis. The principal underlying pathologic mechanism causing bone disease in MM is a shift in the balance of bone formation and bone resorption toward bone resorption, and eventually total dissociation between the 2 processes occurs in latter stages of the disease. During the past decade bisphosphonates have become an important adjunctive treatment in the management of MM, in which they have shown the ability to reduce bony complications associated with the disease. Advances in minimally invasive surgical techniques, such as percutaneous vertebroplasty and kyphoplasty, offer these patients less-invasive options for the treatment of vertebral collapse and restoration of their normal function. This report reviews recent advances in the understanding of bone disease in MM, the role of bisphosphonates in the prevention of skeletal events, and available data regarding percutaneous vertebroplasty and kyphoplasty.
authors.affiliation: Southeastern New Mexico Hematology and Medical Oncology, Carlsbad, USA.
authors.forename: Tahir
authors.initials: T
authors.lastname: Latif
authors.forename: Mohamad A
authors.initials: MA
authors.lastname: Hussein
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000150:complications* / Q000401:mortality; D011379:Prognosis; D016103:Spinal Fractures / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates